Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Industry / Lithuania

2011 Showed Signs Of Recovery But 2012 Set For Weaker Growth

March 2012 | Industry Trend Analysis

BMI View: Lithuania's drug market is expected to post a gradual recovery over the next five years, but with a short-term worsening economic environment, public and private consumption will be under pressure in 2012, supporting our assumption that this year's year-on-year (y-o-y) growth will not be as strong as the bounce posted in 2011. Despite the highest mortality rates in the EU, medicine use, as measured by dosage and units, has declined since 2009. As well as reflecting badly on the attractiveness of this market to drugmakers, this should be a concern for the authorities if they wish to lose the title as the least healthy country in the EU.

To read the full article, please choose one of the following options:

Subcribers please log in

Emerging Europe InsightEmerging Europe Channels Emerging Europe Countries